← Back to Clinical Trials
Recruiting NCT06678841

ELEVATE-HFpEF Clinical Study

◆ AI Clinical Summary

ELEVATE-HFpEF is testing a new pacemaker treatment designed specifically for patients with heart failure who have a normal pumping strength (HFpEF). The study compares a personalized dual chamber pacing approach to standard minimal pacing to see if it can improve heart function and symptoms.

Key Objective: The trial is testing whether personalized dual chamber pacing can reduce symptoms and improve quality of life in patients with heart failure with preserved ejection fraction.

Who to Consider: Patients with heart failure with preserved ejection fraction who may be candidates for pacemaker therapy and are interested in potentially improving their heart function should consider enrolling.

Trial Parameters

Condition Heart Failure With Preserved Ejection Fraction (HFpEF)
Sponsor Medtronic Cardiac Rhythm and Heart Failure
Study Type INTERVENTIONAL
Phase N/A
Enrollment 700
Sex ALL
Min Age 40 Years
Max Age N/A
Start Date 2025-07-09
Completion 2028-08
Interventions
Personalized cardiac pacing

Brief Summary

ELEVATE-HFpEF is a prospective, randomized, controlled, double-blinded, multi-center, global, interventional pivotal study evaluating the safety and efficacy of dual chamber personalized pacing compared to minimal or no pacing for the treatment of patients with heart failure with preserved ejection fraction (HFpEF).

Eligibility Criteria

Inclusion Criteria: 1. Age ≥ 40 years 2. Documented EF ≥50% within the preceding 12 months 3. HFpEF defined as: 1. Documented worsening HF episode (either HF hospitalization or documented urgent clinic visit for HF with intravenous diuretics) within 12-months prior to baseline visit OR 2. Dyspnea on exertion and New York Heart Association (NYHA) ≥ class II symptoms AND AT LEAST ONE OF THE FOLLOWING CRITERIA: * Interstitial / pulmonary edema on prior chest imaging in the last year AND current loop diuretic use for heart failure * Elevated NT-proBNP in the last year defined as \>400 pg/m for patients with no AF or paroxysmal AF, or \>900 pg/ml for patients with ≥persistent AF * Mean pulmonary capillary wedge pressure (PCWP) ≥15 mm Hg or LVEDP ≥16 mm Hg at rest on cardiac catheterization OR pulmonary artery diastolic and wedge pressure (PADP) ≥15 mm Hg at rest on implantable monitor (e.g., CardioMEMs) * Echo criteria defined by ≥2 of: * LV wall thickness ≥ 12 mm * LV mass index (BSA index

Related Trials